
Novo Nordisk A/S (NYSE:NVO) shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.
What To Know: : The European Medicines Agency's Committee for Medicinal Products for Human Use approved an update to the Rybelsus (oral semaglutide) label to reflect cardiovascular benefits demonstrated in the SOUL trial. The phase 3b study showed Rybelsus reduced the risk of major adverse cardiovascular events — a composite of cardiovascular death, heart attack and stroke — by 14% versus placebo in adults with type 2 diabetes at high cardiovascular risk.